BNP Paribas Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
– Sell
-37,058
Closed -$124K – 1121
2016
Q3
$124K Hold
37,058
– – ﹤0.01% 1077
2016
Q2
$116K Hold
37,058
– – ﹤0.01% 1082
2016
Q1
$123K Hold
37,058
– – ﹤0.01% 1061
2015
Q4
$131K Buy
+37,058
New +$155K ﹤0.01% 1060

Other funds holding PDLI

BNP Paribas Asset Management's PDLI Position: Q4 2016 in Review

BNP Paribas Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2016, closing a stake of 37,058 shares — an estimated $124K sold.

BNP Paribas Asset Management first reported a position in PDLI in Q4 2015 and held it in 4 quarters. The position peaked at $131K in Q4 2015. 190 funds tracked by Wall St. Rank hold PDLI as of Q4 2016.

  • BNP Paribas Asset Management reported no remaining PDL BioPharma, Inc. position as of Q4 2016 after selling out during the quarter.
  • BNP Paribas Asset Management sold 37,058 PDL BioPharma, Inc. shares in Q4 2016, an estimated $124K.
  • BNP Paribas Asset Management first reported a position in PDL BioPharma, Inc. in Q4 2015 and held it in 4 quarters.
  • BNP Paribas Asset Management's PDL BioPharma, Inc. position peaked at $131K in Q4 2015.
  • 190 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2016.

Based on BNP Paribas Asset Management's 13F filing for Q4 2016, filed 31 Jan 2017.